Impaired prostate tumorigenesis in Egr1-deficient mice

[1]  Mark A. Watson,et al.  EGR1 Target Genes in Prostate Carcinoma Cells Identified by Microarray Analysis* , 2000, The Journal of Biological Chemistry.

[2]  J. Milbrandt,et al.  Functional Compensation by Egr4 inEgr1-Dependent Luteinizing Hormone Regulation and Leydig Cell Steroidogenesis , 2000, Molecular and Cellular Biology.

[3]  J. DiGiovanni,et al.  Alteration of Egr‐1 mRNA during multistage carcinogenesis in mouse skin , 2000, Molecular carcinogenesis.

[4]  A. Jochemsen,et al.  EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity , 2000, Oncogene.

[5]  B. Berk,et al.  NAB2: a transcriptional brake for activated gene expression in the vessel wall? , 1999, The American journal of pathology.

[6]  E. Silverman,et al.  Pathways of Egr-1-mediated gene transcription in vascular biology. , 1999, The American journal of pathology.

[7]  M. Lagman,et al.  Cyclosporine induces cancer progression by a cell-autonomous mechanism , 1999, Nature.

[8]  L. Khachigian,et al.  New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury , 1999, Nature Medicine.

[9]  P. Humphrey,et al.  A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Milbrandt,et al.  The Transcriptional Corepressor NAB2 Inhibits NGF-induced Differentiation of PC12 Cells , 1998, The Journal of cell biology.

[11]  D. Tindall,et al.  Expression of early growth response genes in human prostate cancer. , 1998, Cancer research.

[12]  T. B. Morrison,et al.  Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. , 1998, BioTechniques.

[13]  J. Milbrandt,et al.  The Transcriptional Corepressor NAB 2 Inhibits NGF-induced Differentiation of PC 12 Cells , 1998 .

[14]  Mihaela Skobe,et al.  Halting angiogenesis suppresses carcinoma cell invasion , 1997, Nature Medicine.

[15]  J. Gordon,et al.  Examining the Role of Paneth Cells in the Small Intestine by Lineage Ablation in Transgenic Mice* , 1997, The Journal of Biological Chemistry.

[16]  E. Barrack.  TGFβ in prostate cancer: A growth inhibitor that can enhance tumorigenicity , 1997 .

[17]  K. A. Klein,et al.  Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice , 1997, Nature Medicine.

[18]  J. Milbrandt,et al.  Luteinizing Hormone Deficiency and Female Infertility in Mice Lacking the Transcription Factor NGFI-A (Egr-1) , 1996, Science.

[19]  Allan Balmain,et al.  TGFβ1 Inhibits the Formation of Benign Skin Tumors, but Enhances Progression to Invasive Spindle Carcinomas in Transgenic Mice , 1996, Cell.

[20]  J. Milbrandt,et al.  Unimpaired macrophage differentiation and activation in mice lacking the zinc finger transplantation factor NGFI-A (EGR1) , 1996, Molecular and cellular biology.

[21]  J. Milbrandt,et al.  NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli , 1996, Molecular and cellular biology.

[22]  Amyj . Williams,et al.  Egr-1-Induced Endothelial Gene Expression: A Common Theme in Vascular Injury , 1996, Science.

[23]  K. Kirsch,et al.  Mader: a novel nuclear protein over expressed in human melanomas. , 1996, Oncogene.

[24]  D. Russell,et al.  Increased expression of early growth response-1 messenger ribonucleic acid in prostatic adenocarcinoma. , 1996, The Journal of urology.

[25]  J. Milbrandt,et al.  Identification of NAB1, a repressor of NGFI-A- and Krox20-mediated transcription. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[26]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Melman,et al.  Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer , 1995, Nature Medicine.

[28]  A. Melman,et al.  Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. , 1995, Nature medicine.

[29]  V. Sukhatme,et al.  Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. , 1995, Progress in nucleic acid research and molecular biology.

[30]  M. Stearns,et al.  Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[31]  R. Bjerkvig,et al.  Heterogeneous response to the growth factors [EGF, PDGF (bb), TGF‐α, bFGF, IL‐2] on glioma spheroid growth, migration and invasion , 1994, International journal of cancer.

[32]  J. Milbrandt,et al.  Transcriptional activity of the zinc finger protein NGFI-A is influenced by its interaction with a cellular factor , 1993, Molecular and cellular biology.

[33]  M. Steiner,et al.  Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. , 1992, Molecular endocrinology.

[34]  M. Brawer,et al.  New relationships between prostatic intraepithelial neoplasia and prostatic carcinoma , 1992, Journal of cellular biochemistry. Supplement.

[35]  L. Liotta,et al.  Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.

[36]  J. Milbrandt,et al.  The zinc finger protein NGFI-A exists in both nuclear and cytoplasmic forms in nerve growth factor-stimulated PC12 cells. , 1990, The Journal of biological chemistry.

[37]  H. Dvorak.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[38]  D. Bostwick,et al.  Intraductal dysplasia: a premalignant lesion of the prostate. , 1986, Human pathology.